Inhibitory effect of rape pollen supercritical CO2 ﬂuid extract against testosterone‑induced benign prostatic hyperplasia in rats

Yang,Bi‑Cheng; Jin,Li‑Li; Yang,Yi‑Fang; Li,Kun; Peng,Dan‑Ming

doi:10.3892/etm.2014.1680

Inhibitory effect of rape pollen supercritical CO2 ﬂuid extract against testosterone‑induced benign prostatic hyperplasia in rats

Authors:
- Bi‑Cheng Yang
- Li‑Li Jin
- Yi‑Fang Yang
- Kun Li
- Dan‑Ming Peng
View Affiliations

Affiliations: Department of Traditional Chinese Medicine, Shanghai Institute of Pharmaceutical Industry, Shanghai 200040, P.R. China, Jiangxi Institute of Traditional Chinese Medicine, Nanchang, Jiangxi 330000, P.R. China
Published online on: April 14, 2014 https://doi.org/10.3892/etm.2014.1680
Pages: 31-37

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Benign prostatic hyperplasia (BPH) can lead to lower urinary tract symptoms. Rape pollen is an apicultural product that is composed of nutritionally valuable and biologically active substances. The aim of the present study was to investigate the protective effect of rape pollen supercritical CO2 fluid extract (SFE‑CO2) in BPH development using a testosterone‑induced BPH rat model. BPH was induced in the experimental groups by daily subcutaneous injections of testosterone for a period of 30 days. Rape pollen SFE‑CO2 was administered daily by oral gavage concurrently with the testosterone injections. Animals were sacrificed at the scheduled termination and the prostates were weighed and subjected to histopathological examination. Testosterone, dihydrotestosterone (DHT), 5α‑reductase and cyclooxygenase‑2 (COX‑2) levels were also measured. BPH‑induced animals exhibited an increase in prostate weight with increased testosterone, DHT, 5α‑reductase and COX‑2 expression levels. However, rape pollen SFE‑CO2 treatment resulted in significant reductions in the prostate index and testosterone, DHT, 5α‑reductase and COX‑2 levels compared with those in BPH‑induced animals. Histopathological examination also demonstrated that rape pollen SFE‑CO2 treatment suppressed testosterone‑induced BPH. These observations indicate that rape pollen SFE‑CO2 inhibits the development of BPH in rats and these effects are closely associated with reductions in DHT, 5α‑reductase and COX‑2 levels. Therefore, the results of the present study clearly indicate that rape pollen SFE‑CO2 extract may be a useful agent in BPH treatment.

View Figures

View References

1	Glynn RJ, Campion EW, Bouchard GR and Silbert JE: The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol. 121:78–90. 1985.PubMed/NCBI
2	Thorpe A and Neal D: Benign prostatic hyperplasia. Lancet. 361:1359–1367. 2003. View Article : Google Scholar
3	Vikram A, Jena GB and Ramarao P: Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia. Prostate. 70:79–89. 2010. View Article : Google Scholar : PubMed/NCBI
4	Füllhase C, Chapple C, Cornu JN, et al: Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol. 64:228–243. 2013.PubMed/NCBI
5	Alaiya AA, Al-Mohanna M, Aslam M, et al: Proteomics-based signature for human benign prostate hyperplasia and prostate adenocarcinoma. Int J Oncol. 38:1047–1057. 2011. View Article : Google Scholar : PubMed/NCBI
6	McNicholas T and Swallow D: Benign prostatic hyperplasia. Surgery (Oxford). 29:282–286. 2011. View Article : Google Scholar
7	Sutcliffe S, Grubb RL III, Platz EA, et al; Urologic Diseases in America Project. Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. BJU Int. 110:1050–1059. 2012. View Article : Google Scholar
8	McConnell JD: Benign prostatic hyperplasia: Editorial comment. Curr Opin Urol. 8:1–3. 1998. View Article : Google Scholar
9	Lin J, Zhou J, Xu W, Zhong X, Hong Z and Peng J: Qianliening capsule treats benign prostatic hyperplasia via suppression of the EGF/STAT3 signaling pathway. Exp Ther Med. 5:1293–1300. 2013.PubMed/NCBI
10	Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J and Mulrow C: Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA. 280:1604–1609. 1998. View Article : Google Scholar : PubMed/NCBI
11	Wilt TJ, Ishani A, Rutks I and MacDonald R: Phytotherapy for benign prostatic hyperplasia. Public Health Nutr. 3:459–472. 2000.PubMed/NCBI
12	Cheng N, Ren N, Gao H, Lei X, Zheng J and Cao W: Antioxidant and hepatoprotective effects of Schisandra chinensis pollen extract on CCl₄-induced acute liver damage in mice. Food Chem Toxicol. 55:234–240. 2013.PubMed/NCBI
13	McCartney HA and Lacey ME: Wind dispersal of pollen from crops of oilseed rape (Brassica napus L.). J Aerosol Sci. 22:467–477. 1991. View Article : Google Scholar
14	Grove MD, Spencer GF, Rohwedder WK, et al: Brassinolide, a plant growth-promoting steroid isolated from Brassica napus pollen. Nature. 281:216–217. 1979. View Article : Google Scholar
15	Hao XL, Zhou YM and Zhang XY: Construction of fingerprint of rape pollen by using HPLC. Agricultural Science & Technology-Hunan. 11(3): 107–109. 1382010.(In Chinese).
16	Veeresh Babu SV, Veeresh B, Patil AA and Warke YB: Lauric acid and myristic acid prevent testosterone induced prostatic hyperplasia in rats. Eur J Pharmacol. 626:262–265. 2010.PubMed/NCBI
17	Barry MJ, Fowler FJ Jr, O’Leary MP, et al: The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 148:1549–1557; discussion 1564. 1992.PubMed/NCBI
18	Yang A, Ren G, Tang L and Jiang W: Effects of soy bean isoflavone on inhibition of benign prostatic hyperplasia and the expressions of NO and NOS of rats. Wei Sheng Yan Jiu. 38:172–174. 2009.(In Chinese).
19	Krieg M, Bartsch W, Thomsen M and Voigt KD: Androgens and estrogens: their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate. J Steroid Biochem. 19:155–161. 1983. View Article : Google Scholar : PubMed/NCBI
20	Chodak GW, Kranc DM, Puy LA, Takeda H, Johnson K and Chang C: Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. J Urol. 147:798–803. 1992.PubMed/NCBI
21	McConnell JD, Bruskewitz R, Walsh P, et al; Finasteride Long-Term Efficacy and Safety Study Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 338:557–563. 1998. View Article : Google Scholar : PubMed/NCBI
22	Gormley GJ, Stoner E, Bruskewitz RC, et al; The Finasteride Study Group. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 327:1185–1191. 1992. View Article : Google Scholar : PubMed/NCBI
23	Isaacs JT and Coffey DS: Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl. 2:33–50. 1989. View Article : Google Scholar : PubMed/NCBI
24	Carson C III and Rittmaster R: The role of dihydrotestosterone in benign prostatic hyperplasia. Urology. 61(4 Suppl 1): 2–7. 2003. View Article : Google Scholar : PubMed/NCBI
25	Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB and Hobbs S: Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 89:2179–2184. 2004. View Article : Google Scholar : PubMed/NCBI
26	Bartsch G, Rittmaster RS and Klocker H: Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Eur Urol. 37:367–380. 2000. View Article : Google Scholar : PubMed/NCBI
27	Kaplan SA, Chung DE, Lee RK, Scofield S and Te AE: A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride. Int J Clin Pract. 66:1052–1055. 2012.
28	Tacklind J, Macdonald R, Rutks I, Stanke JU and Wilt TJ: Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 12:CD0014232012.PubMed/NCBI
29	Azimi H, Khakshur AA, Aghdasi I, Fallah-Tafti M and Abdollahi M: A review of animal and human studies for management of benign prostatic hyperplasia with natural products: perspective of new pharmacological agents. Inflamm Allergy Drug Targets. 11:207–221. 2012. View Article : Google Scholar : PubMed/NCBI
30	Kirschenbaum A, Klausner AP, Lee R, et al: Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology. 56:671–676. 2000. View Article : Google Scholar : PubMed/NCBI
31	Lee SK, Kang JS, Jung da J, et al: Vitamin C suppresses proliferation of the human melanoma cell SK-MEL-2 through the inhibition of cyclooxygenase-2 (COX-2) expression and the modulation of insulin-like growth factor II (IGF-II) production. J Cell Physiol. 216:180–188. 2008. View Article : Google Scholar : PubMed/NCBI
32	Tsujii M and DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 83:493–501. 1995. View Article : Google Scholar : PubMed/NCBI
33	Di Silverio F, Bosman C, Salvatori M, et al: Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Eur Urol. 47:72–79. 2005.PubMed/NCBI
34	Falahatkar S, Mokhtari G, Pourreza F, Asgari SA and Kamran AN: Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. Urology. 72:813–816. 2008. View Article : Google Scholar